Italia markets closed

Novan, Inc. (NOVN)

NasdaqCM - NasdaqCM Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
1,2100-0,0400 (-3,20%)
Al 12:35PM EST. Mercato aperto.
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente1,2500
Aperto1,2400
Denaro1,2100 x 800
Lettera1,2300 x 900
Min-Max giorno1,2000 - 1,2600
Intervallo di 52 settimane0,7900 - 5,0500
Volume88.649
Media Volume215.887
Capitalizzazione29,599M
Beta (5 anni mensile)0,29
Rapporto PE (ttm)N/D
EPS (ttm)-1,8930
Prossima data utili20 feb 2023 - 24 feb 2023
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1A14,50
  • GlobeNewswire

    EPI Health, a Novan Company, Executes a $15.0 Million Financing Agreement

    – Agreement provides immediate access to cash flow – – EPI Health leveraging accounts receivables from commercial product sales to bolster working capital needs – DURHAM, N.C., Dec. 02, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that EPI Health, LLC, a fully consolidated subsidiary of the Company, has signed an accounts receivable-backed factoring agreement, to support its operations, with Bay View Funding, a wholly owned subsidiary of Heritag

  • GlobeNewswire

    Novan to Participate in the Cantor Fitzgerald Medical & Aesthetic Dermatology, Ophthalmology & Medtech Conference

    – Paula Brown Stafford, President and Chief Executive Officer of Novan to participate in a live moderated panel discussion on Thursday, December 8th at 11:00 AM ET – DURHAM, N.C., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that Paula Brown Stafford, President and Chief Executive Officer of Novan, will participate in a panel discussion titled, “Distraction or Destruction?: What’s New/Next in the Industry,” at the Cantor Fitzgerald Medi

  • GlobeNewswire

    Novan Reports Third Quarter 2022 Financial Results and Provides Corporate Update

    – Rhofade prescriptions increased 37% for third quarter year-to-date from prior year – – Continued progress toward submission of berdazimer gel, 10.3% (SB206) New Drug Application (NDA), targeted around the end of 2022 – – Company to host conference call today at 8:30 a.m. ET – DURHAM, N.C., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced its financial and operating results for the third quarter ended September 30, 2022 and provided a corp